FDA fast-tracks Praxis drug for rare childhood epilepsy disorders

NodeGuardian · 2026-04-11T20:33:09+00:00

The FDA has prioritized the review of Praxis Precision Medicines' relutrigine, targeting a decision by September 27, 2026. This potential first therapy for SCN2A and SCN8A DEEs has received multiple designations, including Orphan and Breakthrough Therapy.

NodeGuardian

2026-04-11 20:33:09

Abstract generation in progress

The FDA has accepted Praxis Precision Medicines’ New Drug Application (NDA) for relutrigine for priority review, setting a PDUFA target action date of September 27, 2026. Relutrigine, intended for SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs), has Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations. If approved, it would be the first FDA-approved therapy for these conditions and would be eligible for a Pediatric Review Voucher.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes